Allen, Christopher D
Ashrafi, Kaveh
Atabai, Kamran
Black, Brian L
Blanc, Paul D
Botvinick, Elias H
Boushey, Homer A
Broaddus, V Courtney
Brown, James K
Bruneau, Benoit G
Calfee, Carolyn S.
Caughey, George H
Chang, Andy
Chapman, Harold A
Charo, Israel F
Chawla, Ajay
Chuang, Pao-Tien
Clyman, Ronald I
Conklin, Bruce R
Connolly, Andrew J
Conte, Michael S
Coughlin, Shaun R
Degrado, William F
Deo, Rahul C
Derynck, Rik M
Dobbs, Leland G
Engel, Joanne N
Erle, David J
Fahy, John Vincent
Fineman, Jeffrey R
Ganz, Peter
Gardner, David G
Gartner, Zev Jordan
Glantz, Stanton A
Gold, Warren M
Grabe, Michael D
Gropper, Michael
Grossman, William
Hart, Daniel O
Hata, Akiko
Hawgood, Samuel
Hoffman, Julien I
Huang, Guo
Ingraham, Holly A
Irannejad, Roshanak
Jan, Lily Y
Julius, David J
Jura, Natalia Z
Kan, Yuet W
Kane, John P
Karliner, Joel S
Kornberg, Thomas B
Koth, Laura L
Krauss, Ronald M
Kurtz, Theodore W
Kwok, Pui-Yan
Lazarus, Stephen C
Lee, Randall J
Lim, Wendell A
Ma, Dengke
Mahley, Robert W
Malloy, Mary J.
Mann, Michael J
Matthay, Michael A
Mcdonald, Donald M
Mikawa, Takashi
Minor, Daniel L
Mostov, Keith E
Oishi, Peter E
Olgin, Jeffrey E
Pearce, David
Peng, Tien
Raleigh, David R
Redberg, Rita F
Reiter, Jeremy F.
Rock, Jason R.
Rowitch, David H
Scheinman, Melvin M
Schiller, Nelson B
Seiple, Ian Bass
Sheppard, Dean
Shokat, Kevan M
Shu, Xiaokun
Shum, Anthony K
Simpson, Paul C
Springer, Matthew L
Srivastava, Deepak
Teitel, David F
Vedantham, Vasanth
Von Zastrow, Mark E
Wang, Rong
Wang, Biao
Wang, Lei
Weiner, Orion D
Weiss, Arthur
Weiss, Ethan J
Werb, Zena
Woodruff, Prescott G
Xu, Allison Wanting
Yeghiazarians, Yerem
Zovein, Ann C

CVRI Scientists

Ronald M Krauss, M.D.
Adjunct Professor

Research Interests:

Summary:
Lipoprotein metabolism and risk of cardiovascular disease

Despite recent advances in treatment, cardiovascular disease (CVD) remains the leading cause of death in the US and will soon achieve this status globally. Our group's research is aimed at addressing three major challenges for reducing this enormous disease burden. First, standard diagnostic procedures do not identify a high proportion of children and adults who are at risk for CVD. We have developed and implemented a sophisticated new procedure that, by analyzing individual lipoprotein particles, provides more specific information than that afforded by ordinary cholesterol testing, and hence is capable of improving both the assessment and management of CVD risk. Second, dietary and lifestyle guidance has failed to substantially impact CVD risk factors, particularly those related to overweight and obesity. We have demonstrated that carbohydrate restriction can reverse the high risk lipid profile found in a high proportion of overweight and obese individuals even without weight loss, and that this effect is independent of saturated fat intake. These findings have helped support dietary guidelines that place a greater emphasis on limiting refined carbohydrates than fats. Third, despite the awareness of wide interindividual variability in response to treatments aimed at reducing CVD risk, the potential benefits of applying genomic tools for developing personalized approaches for maximizing CVD risk reduction have not been realized. A major component of our research program has been the application and development of genomic methodology for dissecting genetic influences on the therapeutic responses to statins, the most widely prescribed class of drugs for reducing CVD risk.

CVRIHead